Welcome to our dedicated page for Sagimet Biosciences SEC filings (Ticker: SGMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sagimet Biosciences Inc. (NASDAQ: SGMT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sagimet is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, and its filings offer detailed insight into this development strategy, capital structure, and risk profile.
Through Forms 8-K, Sagimet reports material events such as clinical trial updates, license agreements, accounting firm changes, at-the-market equity sales arrangements, and quarterly financial results. For example, recent 8-K filings describe positive Phase 1 pharmacokinetic data for a denifanstat and resmetirom combination, a global license agreement with TAPI for innovative forms of resmetirom active pharmaceutical ingredient to support a fixed-dose combination program, and financial results for recent quarters. Other 8-Ks outline changes in the company’s independent registered public accounting firm and the establishment of an at-the-market offering program for its Series A common stock.
Investors and analysts can use this page to locate Sagimet’s periodic and current reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on clinical development progress for denifanstat and TVB-3567, funding arrangements, and risk factors related to MASH and acne programs. Forms 4 and other ownership-related filings, when present, can be used to monitor insider transactions in SGMT shares.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand the significance of new 10-Ks, 10-Qs, and 8-Ks. Real-time updates from EDGAR ensure that new Sagimet filings appear promptly, while AI-generated highlights can clarify complex topics such as licensing terms, at-the-market sales agreements, and clinical trial disclosures. This makes the SGMT filings page a practical starting point for reviewing Sagimet’s regulatory history and ongoing obligations.
Sagimet Biosciences (SGMT) received an Amendment No. 1 to Schedule 13G from AP11 Limited and Ascletis Pharma Inc., dated 24 June 2025 and filed 29 June 2025. The filing reports beneficial ownership of 1,504,642 Series A common shares, equal to 4.9 % of the 30,674,855 shares outstanding as cited in Sagimet’s 10 June 2025 Form 8-K.
The reporting persons each claim sole voting and dispositive power over the entire position and report no shared power and no group status. Item 5 confirms “ownership of 5 percent or less,” meaning the investors are no longer 5 % holders under SEC rules. No additional transactions, control arrangements, or contingent rights are disclosed, and the document contains no risk factors, legal matters, or financial projections.
Overall, the amendment simply updates Sagimet’s ownership ledger, signalling that two related offshore entities now hold a sub-5 % passive stake without seeking influence over the issuer’s governance.